Fibroblast Growth Factor 2
Research News and Information

Sunday, November 22, 2009

Prognostic value of proangiogenic cytokines in children with lymphomas.

13 Dec 2009 BACKGROUND: Angiogenesis and proangiogenic cytokines are involved in neoplastic development. The role of these processes in lymphoma formation has not been established. The aim of the study was to assess angiogenesis on the basis of serum levels of ... Read more...

Cellular dichotomy between anchorage-independent growth responses to bFGF and TPA reflects molecular switch in commitment to carcinogenesis.

30 Oct 2009 We have investigated gene expression patterns underlying reversible and irreversible anchorage-independent growth (AIG) phenotypes to identify more sensitive markers of cell transformation for studies directed at interrogating carcinogenesis ... Read more...

Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization.

29 Sep 2009 OBJECTIVE: To evaluate the pharmacologic activity and tolerability of JSM6427, a potent and first selective small-molecule inhibitor of integrin alpha5beta1, in monkey and rabbit models of choroidal neovascularization (CNV). METHODS: JSM6427 ... Read more...

Latest indexed articles for 'Fibroblast Growth Factor 2'

These are the very latest articles for this heading:

• Prognostic value of proangiogenic cytokines in children with lymphomas. 13 Dec 2009
• Cellular dichotomy between anchorage-independent growth responses to bFGF and TPA reflects molecular switch in commitment to carcinogenesis. 30 Oct 2009
• Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. 29 Sep 2009
• Behavior of rat periodontal ligament cells on fibroblast growth factor-2-immobilized titanium surfaces treated by plasma modification. 29 Sep 2009
• Suppression of fibroblast growth factor-2 expression: possible mechanism underlying methylmercury-induced inhibition of the repair of wounded monolayers of cultured human brain microvascular endothelial cells. 29 Sep 2009
• Therapeutic angiogenesis by controlled-release fibroblast growth factor in a patient with Churg-Strauss syndrome complicated by an intractable ischemic leg ulcer. 29 Sep 2009
• Self-renewal and pluripotency is maintained in human embryonic stem cells by co-culture with human fetal liver stromal cells expressing hypoxia inducible factor 1alpha. 29 Sep 2009
• Preparation and culture of rat lens epithelial explants for studying terminal differentiation. 20 Sep 2009
• Deletion of Frs2alpha from the ureteric epithelium causes renal hypoplasia. 7 Sep 2009
• VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B. 2 Sep 2009
• Expansion and characterization of human bone marrow-derived mesenchymal stem cells cultured on fragmin/protamine microparticle-coated matrix with fibroblast growth factor-2 in low serum medium. 30 Aug 2009
• Motion-based angiogenesis analysis: a simple method to quantify blood vessel growth. 30 Aug 2009
• Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. 30 Aug 2009
• Enhanced ex vivo expansion of human adipose tissue-derived mesenchymal stromal cells by fibroblast growth factor-2 and dexamethasone. 30 Aug 2009
• Dose-finding study of fibrin gel-immobilized vascular endothelial growth factor 165 and basic fibroblast growth factor in the arteriovenous loop rat model. 30 Aug 2009
• Differential regulation of blood vessel formation between standard and delayed bone healing. 30 Aug 2009
• The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. 30 Aug 2009
• Trichinella: differential expression of angiogenic factors in macrophages stimulated with antigens from encapsulated and non-encapsulated species. 29 Aug 2009
• Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. 29 Aug 2009
• Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined minimum size. 27 Aug 2009

See a longer list of these articles.

Technical information about 'Fibroblast Growth Factor 2'

Definition: A single-chain polypeptide growth factor that plays a significant role in the process of WOUND HEALING and is a potent inducer of PHYSIOLOGIC ANGIOGENESIS. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to FIBROBLAST GROWTH FACTOR 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (FIBROBLAST GROWTH FACTOR 1).

Registry Number: 103107-01-3

Descriptor UI: D016222

Alternative terms: Fibroblast Growth Factor 2; Cartilage-Derived Growth Factor; Cartilage Derived Growth Factor; Class II Heparin-Binding Growth Factor; FGF-2; FGF 2; Prostatropin; Fibroblast Growth Factor, Basic; Fibroblast Growth Factor-2; HBGF-2; Heparin-Binding Growth Factor Class II; Prostate Epithelial Cell Growth Factor; Basic Fibroblast Growth Factor; FGF2;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Tree Number: D12.644.276.624.120; D12.776.467.624.120; D23.529.624.120;

History Note: 2001(1991); for FIBROBLAST GROWTH FACTOR-2 use FIBROBLAST GROWTH FACTOR 2 (NM) 1995; for PROSTATROPIN use FIBROBLAST GROWTH FACTOR 2 (NM) 1986-2001

Technical Notes: DF: FGFB